Emerging host cell targets for hepatitis C therapy

被引:22
作者
He, Yupeng [1 ]
Duan, Wei
Tan, Seny-Lai
机构
[1] Abbott Labs, Glabal Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA
[2] Deakin Univ, Sch Med, Waurn Ponds, Vic 3217, Australia
[3] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
关键词
D O I
10.1016/j.drudis.2007.01.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic hepatitis C virus (HCV) infection is a major burden on humanity. The current HCV therapy has limited efficacy, and there is pressing need for new and more effective therapies. Host cell factors that are required for HCV infection, replication and/or pathogenesis represent potential therapeutic targets. Of particular interest are cellular receptors that mediate HCV entry, factors that facilitate HCV replication and assembly, and intracellular pathways involving lipid biosynthesis, oxidative stress and innate immune response. A crucial challenge now is to manipulate such cellular targets pharmacologically for chronic HCV treatment, without being limited by side effects.
引用
收藏
页码:209 / 217
页数:9
相关论文
共 111 条
[1]   Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts [J].
Aizaki, H ;
Lee, KJ ;
Sung, VMH ;
Ishiko, H ;
Lai, MMC .
VIROLOGY, 2004, 324 (02) :450-461
[2]   Mutational analysis of hepatitis C virus nonstructural protein 5A: Potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain [J].
Appel, N ;
Pietschmann, T ;
Bartenschlager, R .
JOURNAL OF VIROLOGY, 2005, 79 (05) :3187-3194
[3]   Recent status of HIV-1 gene expression inhibitors [J].
Baba, Masanori .
ANTIVIRAL RESEARCH, 2006, 71 (2-3) :301-306
[4]   Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate [J].
Barth, H ;
Schäfer, C ;
Adah, MI ;
Zhang, FM ;
Linhardt, RJ ;
Toyoda, H ;
Kinoshita-Toyoda, A ;
Toida, T ;
van Kuppevelt, TH ;
Depla, E ;
von Weizsäcker, F ;
Blum, HE ;
Baumert, TF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (42) :41003-41012
[5]  
Bell A, 2006, INT J PARASITOL, V36, P261, DOI 10.1016/j.ijpara.2005.11.003
[6]   A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days [J].
Benson, C. ;
White, J. ;
De Bono, J. ;
O'Donnell, A. ;
Raynaud, F. ;
Cruickshank, C. ;
McGrath, H. ;
Walton, M. ;
Workman, P. ;
Kaye, S. ;
Cassidy, J. ;
Gianella-Borradori, A. ;
Judson, I. ;
Twelves, C. .
BRITISH JOURNAL OF CANCER, 2007, 96 (01) :29-37
[7]  
Billich Andreas, 2002, Curr Opin Investig Drugs, V3, P698
[8]   Efficient initiation of HCV RNA replication in cell culture [J].
Blight, KJ ;
Kolykhalov, AA ;
Rice, CM .
SCIENCE, 2000, 290 (5498) :1972-1974
[9]   Iminosugars as possible broad spectrum anti hepatitis virus agents: the glucovirs and alkovirs [J].
Block, TM ;
Jordan, R .
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 2001, 12 (06) :317-325
[10]   In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus [J].
Bordier, BB ;
Ohkanda, J ;
Liu, P ;
Lee, SY ;
Salazar, FH ;
Marion, PL ;
Ohashi, K ;
Meuse, L ;
Kay, MA ;
Casey, JL ;
Sebti, SM ;
Hamilton, AD ;
Glenn, JS .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (03) :407-414